Resources

​​​​​​​Following a landmark TechBio Week, we reflect with some insights from our flagship conference on the transformative potential for growth of technological advances in the sector.

Cyclana Bio announced the close of a £5 million pre-seed funding round, co-led by NfX and Eka VC, and including Cocoa VC, Wilbe, and Angel investors.

Major 2025 deals from Isomorphic Labs and CHARM Therapeutics validate the sector's maturity as it calls for domestic capital to close the 'scale-up gap.' 

It’s TechBio week and we’re celebrating the UK’s leading role in AI and life sciences with significant investment and interest from global players and our own flagship TechBio UK conference and 2025 report launch. 

How are pharmaceutical companies, policymakers and investors seeking growth amid fast-changing international politics, trade deals, a looming patent cliff, and technological innovation? Our maiden Life sciences and healthcare insights report offers a global perspective on disruptive forces from artificial intelligence to regulatory shifts.

In this blog, NRG Therapeutics co-founder and CEO Dr Neil Miller and Parkinson’s UK Director of Research (and Investor Observer to NRG), Professor David Dexter, explore the history of the relationship and the innovation journey to date.

Good to see support for BIA agendas in government messaging as we continue to push for pension fund reform, attracting the best global talent, UK manufacturing resilience and addressing the challenges of scaling.

Ellie Avni, Senior Director in Employment Tax and Reward at FTI Consulting, explores how the new PISCES platform could reshape EMI and CSOP share option plans – creating fresh opportunities for flexibility and tax-efficient value realisation.

New Moderna Innovation and Technology Centre opened as government further boosts life sciences sector with £50 million fund.

This is my final CEO update in Newscast after 13 years at the BIA. I take up my new role as Executive Chair of the Office for Life Sciences next Monday. Before I do, I want to thank you - my loyal readers - for engaging with my musings over the years, and for your feedback that has improved this blog and my thinking.

This blog explores the key financial trends underpinning the UK's position in the mRNA revolution. The analysis, provided by Wendy Quainoo, the BIA’s Data Insights Executive, highlights the opportunities and challenges ahead, ensuring we can sustain the momentum needed to remain a global leader.

Parkinson’s UK awarded Cellestial Health £55,000 to continue exploring networks of brain cells called astrocytes that may hold answers for new treatments for Parkinson’s.

A new research report, commissioned by Pioneer Group and The Crown Estate, has found that investing £15bn in UK university spinouts over the next 10 years could leverage a further £27bn of co-investment, leading to the creation of over 1700 additional spinouts and 56,000 skilled jobs, and boosting UK science on the global stage.

LBIC announces that its new space in the Apex facility has reached over 50% occupancy just six months after launch, with the addition of Bind Research, its first non-profit tenant, and Twig Bio, a sustainable biotech company.

In the last week, we have been hit by headlines that MSD plans to close its discovery research activities in London and that AstraZeneca is pausing investment due to the UK commercial environment and specifically in response to VPAG outcomes.

A London-based biotech firm that aims to improve infant health with its research into the microbiomes of breast milk has raised £2.5 million.

NRG Therapeutics, an innovative neuroscience company targeting a novel mechanism to address mitochondrial dysfunction, is delighted to announce the closing of its oversubscribed £50m Series B financing.